These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2184878)

  • 61. Management of bladder cancer.
    Whitmore WF
    Curr Probl Cancer; 1979 Jul; 4(1):1-48. PubMed ID: 117974
    [No Abstract]   [Full Text] [Related]  

  • 62. Intralesional recombinant alpha 2a interferon therapy in superficial transitional cell carcinoma of the bladder.
    Di Stasi SM; Tabilio A; Virgili G; Vespasiani G; Porena M; Micali F
    Eur J Cancer; 1991; 27(10):1333. PubMed ID: 1835608
    [No Abstract]   [Full Text] [Related]  

  • 63. The plight of the cancer patient--the double-edged sword.
    Soloway MS
    J Urol; 1983 Aug; 130(2):349. PubMed ID: 6876289
    [No Abstract]   [Full Text] [Related]  

  • 64. Therapeutic options for patients with invasive bladder cancer: the Stanford experience.
    Freiha FS
    Eur Urol; 1988; 14 Suppl 1():43. PubMed ID: 3181243
    [No Abstract]   [Full Text] [Related]  

  • 65. Transitional cell carcinoma: a common sense approach.
    Badalament RA
    J Urol; 1995 Jan; 153(1):61-2. PubMed ID: 7966792
    [No Abstract]   [Full Text] [Related]  

  • 66. Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody.
    Malamitsi J; Zorzos J; Varvarigou AD; Archimandritis S; Dassiou C; Sivolapenko G; Skarlos DV; Serefoglou A; Lykourinas M; Proukakis C
    Cell Biophys; 1994; 24-25():75-81. PubMed ID: 7736542
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recent developments in the treatment of bladder cancer.
    Lance RS; Grossman HB
    Adv Exp Med Biol; 2003; 539(Pt A):3-14. PubMed ID: 15088892
    [No Abstract]   [Full Text] [Related]  

  • 68. Mouse bladder carcinoma as a model to study immune manipulations in man.
    Hellström KE; Hellström I
    Eur Urol; 1988; 14 Suppl 1():17-8. PubMed ID: 3181234
    [No Abstract]   [Full Text] [Related]  

  • 69. [Experimental and clinica studies on antineoplastic agent sensitivity of bladder cancer cells based on their nucleic acid metabolism].
    Ishii Y
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):46-60. PubMed ID: 6865152
    [No Abstract]   [Full Text] [Related]  

  • 70. Huge bladder carcinoma successfully treated with hydrostatic pressure technique. A case report.
    Sabha M; Ek A
    Scand J Urol Nephrol; 1986; 20(4):313-4. PubMed ID: 3810062
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Hyperthermic treatment for the bladder tumor. I. Clinical study (author's transl)].
    Kishimoto T; Okada K; Takimoto Y; Kitajima K; Kumagai S
    Nihon Hinyokika Gakkai Zasshi; 1975 Aug; 66(8):485-92. PubMed ID: 1238845
    [No Abstract]   [Full Text] [Related]  

  • 72. Acute renal insufficiency following hydrostatic pressure treatment: comments on technical procedure.
    Kondo A; Kakel H; Kobayashi O; Mitsuya H
    J Urol; 1975 Jul; 114(1):43-5. PubMed ID: 1142498
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Standardized care pathway for bladder cancer in Sweden. So far lots of pain but little gain.
    Holmäng S; Hedelin H
    Scand J Urol; 2022 Jun; 56(3):233-234. PubMed ID: 35604116
    [No Abstract]   [Full Text] [Related]  

  • 74. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.
    Choudry GA; Stewart PA; Double JA; Krul MR; Naylor B; Flannigan GM; Shah TK; Brown JE; Phillips RM
    Br J Cancer; 2001 Oct; 85(8):1137-46. PubMed ID: 11710826
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?
    Altay B; Girgin C; Kefi A; Cikili N
    Int Urol Nephrol; 2000; 32(1):53-8. PubMed ID: 11057773
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.
    Kiemeney LA; Witjes JA; Verbeek AL; Heijbroek RP; Debruyne FM
    Br J Cancer; 1993 Apr; 67(4):806-12. PubMed ID: 8471440
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BCG in the treatment of superficial cancer of the bladder: a review.
    Friberg S
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):31-6. PubMed ID: 8258992
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy.
    Hall RR; Parmar MK; Richards AB; Smith PH
    BMJ; 1994 Jan; 308(6923):257-60. PubMed ID: 8179678
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
    Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
    Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.
    Zorzos J; Skarlos DV; Pozatzidou P; Zizi A; Bakiras A; Koritsiadis S; Pectasidis D; Koutsioumba P; Epenetos AA; Likourinas M
    Urol Res; 1994; 22(5):323-7. PubMed ID: 7879319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.